COVID-19 vaccine provisional determinations
31 Mar 2023
The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted a number of provisional determinations in relation to COVID-19 vaccines.
The granting of a provisional determination means that the TGA has made a decision that relevant sponsors are now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods (ARTG).
Provisional determination is the first step in the process and does not mean that an application has or will be made, or that the vaccine will be provisionally approved for inclusion in the ARTG. Provisional determinations are effective for 6 months.
Normally for a vaccine to be registered in Australia, a sponsor (usually a pharmaceutical company) is required to submit a complete and comprehensive package of data to the TGA. A formal evaluation is then carried out in multiple stages by technical experts, prior to a decision being made.
The provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data. In order to apply for provisional registration, the sponsor must first apply for a provisional determination. Further information on eligibility criteria can be found at: Provisional determination: A step-by-step guide for prescription medicines.
In making its decision to grant these provisional determinations, the TGA considered all eligibility criteria, including factors such as the evidence of a plan to submit comprehensive clinical data and the seriousness of the current COVID-19 pandemic.
In addition to these determination, the TGA is actively monitoring COVID-19 vaccine development that is occurring both in Australia and around the world, and is part of a network of international regulators that meet regularly to discuss the development of COVID-19 vaccines and the establishment of systems for monitoring the efficacy and safety of COVID-19 vaccines once they have reached the market. The ability to access early data and planned collaboration with international regulators will assist the TGA to expedite the evaluation of any new vaccines without compromising on our strict requirements for safety, quality and effectiveness of products.
|
Sponsor |
Vaccine Name |
Vaccine Type |
Effective date |
Further information |
|---|---|---|---|---|
|
AstraZeneca Pty Ltd |
ChAdOx1-S [recombinant] |
Viral vector |
9 October 2020 (18 years and older) |
|
|
Biocelect Pty Ltd (on behalf of Novavax Inc.) |
NVX-CoV2373 (NUVAXOVID) |
Protein vaccine |
19 January 2021 (18 years and older) 8 March 2022 (12 years and older) |
|
|
Grand Pacific CRO Australia (on behalf of Medigen Vaccine Biologics Corp) |
|
Protein subunit
|
a. 16 November 2021 (18 years and older) b. 02 August 2022 (12 years and older) |
Provisional determination notice
|
|
|
||||
|
Graythan Regulatory Services Pty Ltd (on behalf of Vaxxinity Inc.) |
S1-RBD-sFc Th/CTL Peptides (COSMOVAXX) (Previously referred to as UB-612 COVID-19 Vaccine |
Multitope protein-peptide |
20 September 2022 |
|
|
Janssen-Cilag Pty Ltd |
Ad26.COV2.S (COVID-19 Vaccine Janssen) |
Viral vector |
16 November 2020 (18 years and older) |
|
|
Moderna Australia Pty Ltd |
Elasomeran (SPIKEVAX) |
mRNA |
a. 24 June 2021 (12 years and older) b. 09 November 2021 (<12 years of age) |
|
|
Moderna Australia Pty Ltd |
Elasomeran/ and Imelasomen (SPIKEVAX Bivalent Original/Omicron) (previously referred to as Elasomeran/Elasomeran 0-omicron (SPIKEVAX Bivalent Zero/Omicron)) |
mRNA |
27 April 2022 |
|
|
Moderna Australia Pty Ltd |
Elasomeran and Davesomeran (SPIKEVAX BIVALENT ORIGINAL-OMICRON BA.4-BA.5 |
mRNA |
28 September 2022 |
|
|
Pfizer Australia Pty Ltd |
Tozinameran (COMIRNATY) |
mRNA |
a. 14 October 2020 (16 years and older) b. 11 May 2021 (12-15 years old) c. 12 October 2021 (5-11 years old) d. 28 June 2022 (6 months - <5 years old) |
|
|
Pfizer Australia Pty Ltd |
|
mRNA |
5 July 2022 |
|
|
Pfizer Australia Pty Ltd |
Tozinameran & famtozinameran (COMIRNATY BIVALENT BA.4/BA.5 COVID-19 VACCINE) |
mRNA |
a. 15 November 2022 b. 28 March 2023 (5 years and older) |
|
|
Vaxine Pty Ltd |
Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed) |
Recombinant protein |
15 December 2021 |